Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down – Time to Sell?

Stoke Therapeutics, Inc. (NASDAQ:STOK) gapped down before the market opened on Thursday . The stock had previously closed at $11.95, but opened at $11.50. Stoke Therapeutics shares last traded at $11.69, with a volume of 17,223 shares changing hands.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wedbush restated an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a report on Thursday, July 11th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Thursday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Stoke Therapeutics Trading Up 3.9 %

The company has a 50-day simple moving average of $13.79 and a 200 day simple moving average of $13.70. The company has a market cap of $623.38 million, a P/E ratio of -5.43 and a beta of 0.97.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The firm had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. On average, equities analysts forecast that Stoke Therapeutics, Inc. will post -2.1 EPS for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds have recently made changes to their positions in STOK. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Stoke Therapeutics in the first quarter valued at about $1,224,000. BNP Paribas Financial Markets lifted its position in shares of Stoke Therapeutics by 86.2% in the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after purchasing an additional 6,636 shares during the period. Chase Investment Counsel Corp bought a new position in shares of Stoke Therapeutics during the first quarter valued at approximately $279,000. State Board of Administration of Florida Retirement System purchased a new position in Stoke Therapeutics during the first quarter valued at approximately $141,000. Finally, Vanguard Group Inc. raised its stake in Stoke Therapeutics by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock worth $23,160,000 after buying an additional 67,052 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.